ZFGN - ザフゲン （Zafgen Inc.） ザフゲンZFGNのチャート
ZFGNの企業情報
| symbol | ZFGN |
|---|---|
| 会社名 | Zafgen Inc （ザフゲン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ザフゲン（Zafgen Inc）は臨床段階のバイオ医薬品会社である。同社は独自のメチオニンアミノペプチダーゼ2（MetAP2）生物学プラットフォームを使用して、複雑な代謝疾患の影響を受けた患者のための新規治療法を開発する。製品候補のZGN-1061は、2型糖尿病と他の関連する代謝障害を治療するために使用される新規なフマギリンクラスのMetAP2阻害剤である。2型糖尿病は、慢性多因子性疾患であり、微小血管と大血管疾患の増加をもたらし、心臓血管疾患、脳卒中及び腎不全による死亡リスクを増加させる。MetAP2の開発候補のZGN-1258は、皮下注射によって投与される。ZGN-1258はプラダーウィリー症候群（PWS）の治療に使用される。PWSは、過食症、制御不能な飢餓及びその関連行動、並びに肥満を含む生理学的、認知的及び行動的症状を特徴とする、まれで複雑な遺伝的障害である。 ザフゲンは米国のバイオ医薬品会社。肥満の患者の健康に焦点を当てる。同社の製品「Beloranib」は、肥満や過食症を含む複数の適応症に対する治療法で週2回皮下注射する。また、プラダ―・ウィリ―症候群や頭蓋咽頭腫と関連する肥満症、一般集団における深刻な肥満などの治療に使用される。本社はボストン。 Zafgen, Inc. is a biopharmaceutical company, which engages in the development of novel therapies for patients affected by complex metabolic diseases. It focuses on the study of MetAP2 inhibitors in both common and rare metabolic disorders. The firm also advancing programs for type 2 diabetes, Prader-Willi syndrome, and liver diseases. The company was founded on November 22, 2005 and is headquartered in Boston, MA. |
| 本社所在地 | 175 Portland Street 4th Floor Boston MA 02114 USA |
| 代表者氏名 | Peter Barrett ピーター・バレット |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 617-622-4003 |
| 設立年月日 | 38657 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 35人 |
| url | www.zafgen.com |
| nasdaq_url | https://www.nasdaq.com/symbol/zfgn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -57.25900 |
| 終値（lastsale） | 10.165 |
| 時価総額（marketcap） | 374128832.515 |
| 時価総額 | 時価総額（百万ドル） 377.99340 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 322.46440 |
| 当期純利益 | 当期純利益（百万ドル） -57.40100 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Zafgen Inc revenues was not reported. Net loss increased 20% to $31.7M. Higher net loss reflects Research and Development increase of 16% to $21.4M (expense) Stock-based Compensation in R&D increase of 87% to $3.2M (expense) Interest Expense increase from $126K to $924K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.96 to -$1.15. |
ZFGNのテクニカル分析
ZFGNのニュース
Zafgen (NASDAQ:ZFGN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS 2019/11/07 22:46:44 Modern Readers
Zafgen (NASDAQ:ZFGN) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.03, Fidelity Earnings reports. NASDAQ ZFGN traded up $0.02 during mid-day trading on Thursday, reaching $0.76. 457,450 shares of the company’s stock traded hands, compared to its average volume of 359,394. […]
The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication 2019/09/06 11:27:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 5) Bioanalytical Systems, Inc. (NASDAQ: BASI ) NextCure Inc (NASDAQ: NXTC ) Pfenex Inc (NYSE: PFNX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 5) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) BioNano Genomics Inc (NASDAQ: BNGO ) Endologix, Inc. (NASDAQ: ELGX ) Mallinckrodt PLC (NYSE: MNK ) ( retreated amid reports of restructuring ahead of Cleveland opioid litigation) Merit Medical Systems, Inc. (NASDAQ: MMSI ) VBI Vaccines Inc (NASDAQ: VBIV ) Zafgen Inc (NASDAQ: ZFGN ) ( announced decision to explore strategic options) See Also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Neon's Process To Predict Neoantigens To Control Tumor Growth Published In Scientific Journal Neon Therapeutics Inc (NASDAQ: NTGN ) announced publication in the scientific journal "Immunity," a breakthrough process for predicting which neoantigens will be presented by MHC Class II molecules in the tumor microenvironment.
Zafgen To Explore Strategic Options, With No Near-Term Resolution For Diabetes Drug 2019/09/05 15:24:19 Benzinga
Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics and into the commercialization stage. Earlier this week, Abeona Therapeutics Inc (NASDAQ: ABEO ) opted to explore strategic options, and another biotech has now made a similar announcement. What Happened Zafgen Inc (NASDAQ: ZFGN ), a micro-cap biopharma, announced Thursday that it plans to explore strategic options to maximize shareholder value. The strategic alternatives being evaluated include an acquisition, merger, business combination, in-licensing or other strategic transaction involving the company and its … Full story available on Benzinga.com
The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO 2019/08/27 11:29:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 26) Advaxis, Inc. (NASDAQ: ADXS ) Arbutus Biopharma Corp (NASDAQ: ABUS ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Avanos Medical Inc (NYSE: AVNS ) Cancer Genetics Inc (NASDAQ: CGIX ) Clearside Biomedical Inc (NASDAQ: CLSD ) Elanco Animal Health Inc (NYSE: ELAN )(Bank of America downgraded the shares to Neutral) Neurometrix Inc (NASDAQ: NURO ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tocagen Inc (NASDAQ: TOCA ) Unity Biotechnology Inc (NASDAQ: UBX ) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Nuvectra To Explore Strategic Options Nuvectra Corp (NASDAQ: NVTR ) announced its decision to explore strategic alternatives to …
How Many Zafgen, Inc. (NASDAQ:ZFGN) Shares Do Institutions Own? 2019/07/18 17:17:45 Yahoo Finance
The big shareholder groups in Zafgen, Inc. (NASDAQ:ZFGN) have power over the company. Insiders often own a large chunk…
Zafgen (NASDAQ:ZFGN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS 2019/11/07 22:46:44 Modern Readers
Zafgen (NASDAQ:ZFGN) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.03, Fidelity Earnings reports. NASDAQ ZFGN traded up $0.02 during mid-day trading on Thursday, reaching $0.76. 457,450 shares of the company’s stock traded hands, compared to its average volume of 359,394. […]
The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication 2019/09/06 11:27:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 5) Bioanalytical Systems, Inc. (NASDAQ: BASI ) NextCure Inc (NASDAQ: NXTC ) Pfenex Inc (NYSE: PFNX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 5) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) BioNano Genomics Inc (NASDAQ: BNGO ) Endologix, Inc. (NASDAQ: ELGX ) Mallinckrodt PLC (NYSE: MNK ) ( retreated amid reports of restructuring ahead of Cleveland opioid litigation) Merit Medical Systems, Inc. (NASDAQ: MMSI ) VBI Vaccines Inc (NASDAQ: VBIV ) Zafgen Inc (NASDAQ: ZFGN ) ( announced decision to explore strategic options) See Also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Neon's Process To Predict Neoantigens To Control Tumor Growth Published In Scientific Journal Neon Therapeutics Inc (NASDAQ: NTGN ) announced publication in the scientific journal "Immunity," a breakthrough process for predicting which neoantigens will be presented by MHC Class II molecules in the tumor microenvironment.
Zafgen To Explore Strategic Options, With No Near-Term Resolution For Diabetes Drug 2019/09/05 15:24:19 Benzinga
Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics and into the commercialization stage. Earlier this week, Abeona Therapeutics Inc (NASDAQ: ABEO ) opted to explore strategic options, and another biotech has now made a similar announcement. What Happened Zafgen Inc (NASDAQ: ZFGN ), a micro-cap biopharma, announced Thursday that it plans to explore strategic options to maximize shareholder value. The strategic alternatives being evaluated include an acquisition, merger, business combination, in-licensing or other strategic transaction involving the company and its … Full story available on Benzinga.com
The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO 2019/08/27 11:29:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 26) Advaxis, Inc. (NASDAQ: ADXS ) Arbutus Biopharma Corp (NASDAQ: ABUS ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Avanos Medical Inc (NYSE: AVNS ) Cancer Genetics Inc (NASDAQ: CGIX ) Clearside Biomedical Inc (NASDAQ: CLSD ) Elanco Animal Health Inc (NYSE: ELAN )(Bank of America downgraded the shares to Neutral) Neurometrix Inc (NASDAQ: NURO ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tocagen Inc (NASDAQ: TOCA ) Unity Biotechnology Inc (NASDAQ: UBX ) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Nuvectra To Explore Strategic Options Nuvectra Corp (NASDAQ: NVTR ) announced its decision to explore strategic alternatives to …